Trials / Completed
CompletedNCT00411528
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
A Randomized Multicenter Phase II Trial of Patupilone (EPO906) Plus Prednisone Versus Docetaxel Plus Prednisone in Patients With Metastatic Hormone Refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 185 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and the effects on patient-reported outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Patupilone | |
| DRUG | prednisone | |
| DRUG | docetaxel |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2006-12-14
- Last updated
- 2020-12-17
Locations
32 sites across 8 countries: United States, Australia, Belgium, France, Germany, Italy, Singapore, Spain
Source: ClinicalTrials.gov record NCT00411528. Inclusion in this directory is not an endorsement.